memantine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| adamantane derivatives | 1679 | 19982-08-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 20 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.32 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 48 % | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 16, 2003 | FDA | FOREST LABS LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Fall | 272.91 | 14.41 | 464 | 18408 | 334468 | 50251784 |
| Confusional state | 213.16 | 14.41 | 302 | 18570 | 185626 | 50400626 |
| Agitation | 208.67 | 14.41 | 167 | 18705 | 53217 | 50533035 |
| Hallucination | 161.42 | 14.41 | 136 | 18736 | 46521 | 50539731 |
| Aggression | 157.18 | 14.41 | 98 | 18774 | 21018 | 50565234 |
| Abnormal behaviour | 138.20 | 14.41 | 88 | 18784 | 19570 | 50566682 |
| Dementia | 133.79 | 14.41 | 80 | 18792 | 15917 | 50570335 |
| Somnolence | 114.19 | 14.41 | 206 | 18666 | 154779 | 50431473 |
| Delirium | 103.52 | 14.41 | 97 | 18775 | 38095 | 50548157 |
| Body tinea | 101.94 | 14.41 | 32 | 18840 | 1295 | 50584957 |
| Myoclonus | 99.77 | 14.41 | 64 | 18808 | 14406 | 50571846 |
| Bradycardia | 84.64 | 14.41 | 112 | 18760 | 64314 | 50521938 |
| Infection susceptibility increased | 84.60 | 14.41 | 33 | 18839 | 2551 | 50583701 |
| Inhibitory drug interaction | 81.98 | 14.41 | 31 | 18841 | 2202 | 50584050 |
| Psychomotor hyperactivity | 79.02 | 14.41 | 47 | 18825 | 9254 | 50576998 |
| Seizure | 73.49 | 14.41 | 146 | 18726 | 117728 | 50468524 |
| Product administration interrupted | 71.54 | 14.41 | 23 | 18849 | 1006 | 50585246 |
| Glucose tolerance impaired | 65.86 | 14.41 | 34 | 18838 | 5084 | 50581168 |
| Hallucination, visual | 60.74 | 14.41 | 50 | 18822 | 16532 | 50569720 |
| Loss of consciousness | 59.98 | 14.41 | 125 | 18747 | 104228 | 50482024 |
| Rheumatoid arthritis | 59.92 | 14.41 | 4 | 18868 | 202546 | 50383706 |
| Urinary tract infection | 57.62 | 14.41 | 199 | 18673 | 223821 | 50362431 |
| Impaired quality of life | 55.12 | 14.41 | 32 | 18840 | 6024 | 50580228 |
| Sialoadenitis | 53.45 | 14.41 | 20 | 18852 | 1380 | 50584872 |
| Disorientation | 53.37 | 14.41 | 66 | 18806 | 35418 | 50550834 |
| Delusion | 52.08 | 14.41 | 38 | 18834 | 10531 | 50575721 |
| Alopecia | 51.28 | 14.41 | 14 | 18858 | 245033 | 50341219 |
| Joint swelling | 49.51 | 14.41 | 15 | 18857 | 245271 | 50340981 |
| Arthralgia | 48.96 | 14.41 | 55 | 18817 | 438647 | 50147605 |
| Purpura | 47.41 | 14.41 | 35 | 18837 | 9876 | 50576376 |
| Drug hypersensitivity | 46.08 | 14.41 | 18 | 18854 | 250992 | 50335260 |
| Infusion related reaction | 45.64 | 14.41 | 5 | 18867 | 169552 | 50416700 |
| Maternal exposure during pregnancy | 44.86 | 14.41 | 4 | 18868 | 159774 | 50426478 |
| Encephalopathy | 44.85 | 14.41 | 59 | 18813 | 33652 | 50552600 |
| Orthostatic hypotension | 44.59 | 14.41 | 55 | 18817 | 29426 | 50556826 |
| Dysphagia | 43.52 | 14.41 | 92 | 18780 | 77426 | 50508826 |
| Chorea | 43.47 | 14.41 | 17 | 18855 | 1323 | 50584929 |
| Pain | 43.30 | 14.41 | 95 | 18777 | 578808 | 50007444 |
| Syncope | 43.23 | 14.41 | 109 | 18763 | 102893 | 50483359 |
| Speech disorder | 42.40 | 14.41 | 59 | 18813 | 35489 | 50550763 |
| Dyskinesia | 42.18 | 14.41 | 52 | 18820 | 27809 | 50558443 |
| Hyponatraemia | 41.67 | 14.41 | 103 | 18769 | 96036 | 50490216 |
| Aphasia | 41.24 | 14.41 | 52 | 18820 | 28442 | 50557810 |
| Cognitive disorder | 40.81 | 14.41 | 65 | 18807 | 44058 | 50542194 |
| Bone density decreased | 39.73 | 14.41 | 33 | 18839 | 11042 | 50575210 |
| Swelling | 39.25 | 14.41 | 13 | 18859 | 200859 | 50385393 |
| Hypernatraemia | 38.79 | 14.41 | 26 | 18846 | 6295 | 50579957 |
| Electrocardiogram PR prolongation | 38.76 | 14.41 | 13 | 18859 | 650 | 50585602 |
| Urinary retention | 38.23 | 14.41 | 48 | 18824 | 26142 | 50560110 |
| Mental status changes | 37.13 | 14.41 | 56 | 18816 | 36216 | 50550036 |
| Sinusitis | 37.09 | 14.41 | 9 | 18863 | 170549 | 50415703 |
| Dementia Alzheimer's type | 36.68 | 14.41 | 14 | 18858 | 1020 | 50585232 |
| Contraindicated product administered | 36.26 | 14.41 | 6 | 18866 | 148952 | 50437300 |
| Lack of spontaneous speech | 36.04 | 14.41 | 9 | 18863 | 154 | 50586098 |
| Systemic lupus erythematosus | 35.75 | 14.41 | 5 | 18867 | 140617 | 50445635 |
| Drug interaction | 35.53 | 14.41 | 158 | 18714 | 199463 | 50386789 |
| Poor quality sleep | 35.28 | 14.41 | 37 | 18835 | 16609 | 50569643 |
| Arthropathy | 34.99 | 14.41 | 8 | 18864 | 157898 | 50428354 |
| Altered state of consciousness | 34.96 | 14.41 | 42 | 18830 | 21868 | 50564384 |
| Death | 34.94 | 14.41 | 224 | 18648 | 325155 | 50261097 |
| Gait disturbance | 34.87 | 14.41 | 129 | 18743 | 149876 | 50436376 |
| Product adhesion issue | 34.22 | 14.41 | 21 | 18851 | 4371 | 50581881 |
| Cellulitis | 34.06 | 14.41 | 79 | 18793 | 70719 | 50515533 |
| Exposure during pregnancy | 34.04 | 14.41 | 3 | 18869 | 121012 | 50465240 |
| Cerebral atrophy | 33.32 | 14.41 | 21 | 18851 | 4580 | 50581672 |
| Depressed level of consciousness | 33.11 | 14.41 | 65 | 18807 | 51888 | 50534364 |
| Lethargy | 32.91 | 14.41 | 63 | 18809 | 49369 | 50536883 |
| Dermatitis atopic | 32.77 | 14.41 | 19 | 18853 | 3567 | 50582685 |
| Sedation | 32.39 | 14.41 | 48 | 18824 | 30562 | 50555690 |
| Incoherent | 32.39 | 14.41 | 20 | 18852 | 4210 | 50582042 |
| Accidental overdose | 32.08 | 14.41 | 38 | 18834 | 19495 | 50566757 |
| Behaviour disorder | 31.16 | 14.41 | 16 | 18856 | 2364 | 50583888 |
| Hyperlipidaemia | 30.35 | 14.41 | 35 | 18837 | 17455 | 50568797 |
| Posture abnormal | 30.15 | 14.41 | 15 | 18857 | 2074 | 50584178 |
| Impaired work ability | 30.13 | 14.41 | 31 | 18841 | 13609 | 50572643 |
| Anxiety disorder | 29.74 | 14.41 | 18 | 18854 | 3655 | 50582597 |
| Dyspnoea | 29.63 | 14.41 | 105 | 18767 | 547503 | 50038749 |
| Immobile | 29.13 | 14.41 | 20 | 18852 | 5034 | 50581218 |
| Treatment failure | 28.51 | 14.41 | 8 | 18864 | 137629 | 50448623 |
| Electrocardiogram QT prolonged | 28.44 | 14.41 | 61 | 18811 | 51825 | 50534427 |
| Gait inability | 28.18 | 14.41 | 50 | 18822 | 36977 | 50549275 |
| Hip fracture | 27.92 | 14.41 | 41 | 18831 | 25890 | 50560362 |
| Dehydration | 27.36 | 14.41 | 121 | 18751 | 152328 | 50433924 |
| Drug intolerance | 27.19 | 14.41 | 25 | 18847 | 219079 | 50367173 |
| Metastatic neoplasm | 26.85 | 14.41 | 17 | 18855 | 3737 | 50582515 |
| Belligerence | 26.68 | 14.41 | 7 | 18865 | 147 | 50586105 |
| Decreased appetite | 26.46 | 14.41 | 146 | 18726 | 200777 | 50385475 |
| Pneumonia aspiration | 26.39 | 14.41 | 44 | 18828 | 30960 | 50555292 |
| Memory impairment | 26.28 | 14.41 | 77 | 18795 | 79283 | 50506969 |
| Dizziness | 26.01 | 14.41 | 219 | 18653 | 346150 | 50240102 |
| Febrile neutropenia | 25.96 | 14.41 | 3 | 18869 | 97664 | 50488588 |
| Emotional poverty | 25.94 | 14.41 | 8 | 18864 | 305 | 50585947 |
| Abdominal discomfort | 25.82 | 14.41 | 29 | 18843 | 231612 | 50354640 |
| Akinesia | 25.36 | 14.41 | 12 | 18860 | 1487 | 50584765 |
| Tremor | 25.18 | 14.41 | 97 | 18775 | 114806 | 50471446 |
| Asthenia | 25.16 | 14.41 | 204 | 18668 | 318838 | 50267414 |
| Hypophagia | 24.48 | 14.41 | 40 | 18832 | 27688 | 50558564 |
| Oral herpes | 24.12 | 14.41 | 34 | 18838 | 20691 | 50565561 |
| Pulmonary embolism | 24.06 | 14.41 | 88 | 18784 | 101616 | 50484636 |
| Inappropriate antidiuretic hormone secretion | 23.99 | 14.41 | 27 | 18845 | 13116 | 50573136 |
| Nasopharyngitis | 23.95 | 14.41 | 22 | 18850 | 192905 | 50393347 |
| Hypersomnia | 23.85 | 14.41 | 29 | 18843 | 15285 | 50570967 |
| Cerebral haemorrhage | 23.85 | 14.41 | 39 | 18833 | 27013 | 50559239 |
| Head injury | 23.05 | 14.41 | 36 | 18836 | 23984 | 50562268 |
| Skin disorder | 23.04 | 14.41 | 36 | 18836 | 23994 | 50562258 |
| Failure to thrive | 22.92 | 14.41 | 19 | 18853 | 6339 | 50579913 |
| Stomatitis | 22.71 | 14.41 | 5 | 18867 | 101339 | 50484913 |
| Immune thrombocytopenia | 22.70 | 14.41 | 22 | 18850 | 8995 | 50577257 |
| Pain in extremity | 22.69 | 14.41 | 42 | 18830 | 272823 | 50313429 |
| Akathisia | 22.47 | 14.41 | 21 | 18851 | 8208 | 50578044 |
| Schizophrenia | 22.39 | 14.41 | 20 | 18852 | 7377 | 50578875 |
| Disturbance in attention | 22.31 | 14.41 | 41 | 18831 | 31145 | 50555107 |
| Balance disorder | 21.96 | 14.41 | 67 | 18805 | 70523 | 50515729 |
| Restlessness | 21.80 | 14.41 | 36 | 18836 | 25137 | 50561115 |
| Hypersensitivity | 21.80 | 14.41 | 29 | 18843 | 215132 | 50371120 |
| Epilepsy | 21.65 | 14.41 | 33 | 18839 | 21534 | 50564718 |
| Headache | 21.26 | 14.41 | 107 | 18765 | 506428 | 50079824 |
| Diet refusal | 21.14 | 14.41 | 8 | 18864 | 569 | 50585683 |
| Pyrexia | 21.13 | 14.41 | 72 | 18800 | 380131 | 50206121 |
| Wrong patient received product | 21.03 | 14.41 | 11 | 18861 | 1689 | 50584563 |
| Lower respiratory tract infection | 20.73 | 14.41 | 5 | 18867 | 95196 | 50491056 |
| Device pacing issue | 20.70 | 14.41 | 5 | 18867 | 74 | 50586178 |
| Medication error | 20.42 | 14.41 | 43 | 18829 | 36061 | 50550191 |
| Stupor | 20.23 | 14.41 | 14 | 18858 | 3569 | 50582683 |
| Crying | 20.15 | 14.41 | 31 | 18841 | 20385 | 50565867 |
| Vitamin D deficiency | 20.09 | 14.41 | 23 | 18849 | 11379 | 50574873 |
| Drug-device interaction | 20.05 | 14.41 | 5 | 18867 | 85 | 50586167 |
| Rash | 19.75 | 14.41 | 90 | 18782 | 437381 | 50148871 |
| Therapeutic drug monitoring analysis not performed | 19.59 | 14.41 | 8 | 18864 | 697 | 50585555 |
| Abdominal pain | 19.07 | 14.41 | 37 | 18835 | 236191 | 50350061 |
| Nausea | 18.64 | 14.41 | 171 | 18701 | 705227 | 49881025 |
| Floppy iris syndrome | 18.63 | 14.41 | 5 | 18867 | 115 | 50586137 |
| Metastases to central nervous system | 18.61 | 14.41 | 22 | 18850 | 11260 | 50574992 |
| Anger | 18.53 | 14.41 | 22 | 18850 | 11311 | 50574941 |
| Aptyalism | 18.50 | 14.41 | 7 | 18865 | 498 | 50585754 |
| Parkinson's disease | 18.50 | 14.41 | 9 | 18863 | 1186 | 50585066 |
| Angina pectoris | 18.19 | 14.41 | 34 | 18838 | 26154 | 50560098 |
| Subdural haematoma | 17.74 | 14.41 | 23 | 18849 | 12924 | 50573328 |
| Anaemia neonatal | 17.43 | 14.41 | 6 | 18866 | 325 | 50585927 |
| Retinopathy of prematurity | 17.32 | 14.41 | 6 | 18866 | 331 | 50585921 |
| Neutropenia | 17.05 | 14.41 | 18 | 18854 | 147947 | 50438305 |
| Blood creatine phosphokinase increased | 16.80 | 14.41 | 33 | 18839 | 26334 | 50559918 |
| Diabetic hyperosmolar coma | 16.79 | 14.41 | 6 | 18866 | 363 | 50585889 |
| Oroantral fistula | 16.38 | 14.41 | 5 | 18867 | 184 | 50586068 |
| Therapeutic product effect decreased | 16.30 | 14.41 | 16 | 18856 | 136034 | 50450218 |
| Drug ineffective | 16.29 | 14.41 | 212 | 18660 | 819121 | 49767131 |
| Non-24-hour sleep-wake disorder | 16.29 | 14.41 | 3 | 18869 | 10 | 50586242 |
| Parkinsonism | 15.85 | 14.41 | 18 | 18854 | 8829 | 50577423 |
| Intestinal pseudo-obstruction | 15.79 | 14.41 | 7 | 18865 | 747 | 50585505 |
| Cataract | 15.75 | 14.41 | 46 | 18826 | 47254 | 50538998 |
| Incontinence | 15.70 | 14.41 | 19 | 18853 | 9966 | 50576286 |
| Back pain | 15.64 | 14.41 | 37 | 18835 | 219993 | 50366259 |
| Granulocytopenia | 15.55 | 14.41 | 14 | 18858 | 5217 | 50581035 |
| Amyloid related imaging abnormality-oedema/effusion | 15.31 | 14.41 | 3 | 18869 | 15 | 50586237 |
| Application site rash | 15.20 | 14.41 | 10 | 18862 | 2347 | 50583905 |
| Discomfort | 15.13 | 14.41 | 11 | 18861 | 108369 | 50477883 |
| Irritability | 15.09 | 14.41 | 33 | 18839 | 28393 | 50557859 |
| Pleurothotonus | 14.91 | 14.41 | 8 | 18864 | 1293 | 50584959 |
| Pruritus | 14.86 | 14.41 | 55 | 18817 | 283513 | 50302739 |
| Eating disorder | 14.65 | 14.41 | 23 | 18849 | 15386 | 50570866 |
| Apathy | 14.62 | 14.41 | 16 | 18856 | 7532 | 50578720 |
| Lung neoplasm malignant | 14.57 | 14.41 | 23 | 18849 | 15461 | 50570791 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hallucination | 279.38 | 16.16 | 199 | 13034 | 44513 | 29516781 |
| Confusional state | 215.75 | 16.16 | 275 | 12958 | 127602 | 29433692 |
| Fall | 209.43 | 16.16 | 321 | 12912 | 176857 | 29384437 |
| Dementia | 138.40 | 16.16 | 78 | 13155 | 11580 | 29549714 |
| Aggression | 124.84 | 16.16 | 113 | 13120 | 35428 | 29525866 |
| Abnormal behaviour | 110.94 | 16.16 | 88 | 13145 | 23039 | 29538255 |
| Somnolence | 105.99 | 16.16 | 167 | 13066 | 93788 | 29467506 |
| Agitation | 87.18 | 16.16 | 111 | 13122 | 51193 | 29510101 |
| Product administration interrupted | 82.96 | 16.16 | 21 | 13212 | 314 | 29560980 |
| Gait disturbance | 79.37 | 16.16 | 128 | 13105 | 73221 | 29488073 |
| Pleurothotonus | 71.16 | 16.16 | 24 | 13209 | 1014 | 29560280 |
| Delusion | 70.04 | 16.16 | 50 | 13183 | 11166 | 29550128 |
| Delirium | 66.52 | 16.16 | 85 | 13148 | 39312 | 29521982 |
| Death | 58.53 | 16.16 | 304 | 12929 | 341780 | 29219514 |
| Sopor | 55.41 | 16.16 | 43 | 13190 | 10891 | 29550403 |
| Orthostatic hypotension | 53.45 | 16.16 | 58 | 13175 | 22571 | 29538723 |
| Eosinophilic pleural effusion | 51.13 | 16.16 | 13 | 13220 | 198 | 29561096 |
| Prescribed underdose | 42.48 | 16.16 | 32 | 13201 | 7754 | 29553540 |
| Product adhesion issue | 42.23 | 16.16 | 18 | 13215 | 1453 | 29559841 |
| Bradycardia | 41.43 | 16.16 | 91 | 13142 | 65538 | 29495756 |
| Pneumonia aspiration | 38.16 | 16.16 | 63 | 13170 | 36674 | 29524620 |
| Spur cell anaemia | 37.34 | 16.16 | 8 | 13225 | 54 | 29561240 |
| Memory impairment | 35.83 | 16.16 | 61 | 13172 | 36409 | 29524885 |
| Gait inability | 34.76 | 16.16 | 42 | 13191 | 18333 | 29542961 |
| Febrile neutropenia | 33.76 | 16.16 | 5 | 13228 | 112235 | 29449059 |
| Hallucination, visual | 32.88 | 16.16 | 37 | 13196 | 14978 | 29546316 |
| Asthenia | 32.37 | 16.16 | 185 | 13048 | 215065 | 29346229 |
| Balance disorder | 32.28 | 16.16 | 58 | 13175 | 36112 | 29525182 |
| Foaming at mouth | 31.85 | 16.16 | 12 | 13221 | 701 | 29560593 |
| Depressed level of consciousness | 31.40 | 16.16 | 58 | 13175 | 36884 | 29524410 |
| Loss of consciousness | 31.20 | 16.16 | 88 | 13145 | 73968 | 29487326 |
| Subdural haematoma | 30.28 | 16.16 | 39 | 13194 | 18154 | 29543140 |
| Syncope | 29.81 | 16.16 | 92 | 13141 | 81279 | 29480015 |
| Urinary tract infection | 29.53 | 16.16 | 85 | 13148 | 72269 | 29489025 |
| Dementia with Lewy bodies | 29.46 | 16.16 | 11 | 13222 | 627 | 29560667 |
| Condition aggravated | 29.10 | 16.16 | 136 | 13097 | 146159 | 29415135 |
| Dysphagia | 28.98 | 16.16 | 71 | 13162 | 54855 | 29506439 |
| Hyporesponsive to stimuli | 28.50 | 16.16 | 12 | 13221 | 939 | 29560355 |
| Hypersomnia | 26.14 | 16.16 | 28 | 13205 | 10726 | 29550568 |
| Tremor | 25.87 | 16.16 | 82 | 13151 | 73456 | 29487838 |
| Inappropriate antidiuretic hormone secretion | 25.76 | 16.16 | 28 | 13205 | 10904 | 29550390 |
| Bradyarrhythmia | 25.50 | 16.16 | 14 | 13219 | 1971 | 29559323 |
| Mixed dementia | 25.47 | 16.16 | 8 | 13225 | 269 | 29561025 |
| Speech disorder | 25.32 | 16.16 | 41 | 13192 | 23475 | 29537819 |
| Mental status changes | 25.00 | 16.16 | 51 | 13182 | 34876 | 29526418 |
| Product dose omission issue | 24.86 | 16.16 | 97 | 13136 | 96286 | 29465008 |
| Psychomotor hyperactivity | 24.73 | 16.16 | 24 | 13209 | 8189 | 29553105 |
| Dyskinesia | 24.41 | 16.16 | 37 | 13196 | 20024 | 29541270 |
| Cognitive disorder | 23.99 | 16.16 | 40 | 13193 | 23459 | 29537835 |
| Nonspecific reaction | 23.20 | 16.16 | 11 | 13222 | 1140 | 29560154 |
| Urinary incontinence | 22.37 | 16.16 | 32 | 13201 | 16449 | 29544845 |
| Myoclonus | 21.32 | 16.16 | 28 | 13205 | 13281 | 29548013 |
| Conduction disorder | 20.98 | 16.16 | 12 | 13221 | 1828 | 29559466 |
| Disorientation | 19.83 | 16.16 | 42 | 13191 | 29473 | 29531821 |
| Sinus bradycardia | 19.50 | 16.16 | 25 | 13208 | 11578 | 29549716 |
| Accidental overdose | 19.38 | 16.16 | 31 | 13202 | 17562 | 29543732 |
| Hypernatraemia | 19.32 | 16.16 | 20 | 13213 | 7366 | 29553928 |
| Decreased appetite | 19.28 | 16.16 | 121 | 13112 | 145221 | 29416073 |
| Drug hypersensitivity | 18.50 | 16.16 | 4 | 13229 | 68402 | 29492892 |
| Dysstasia | 18.29 | 16.16 | 23 | 13210 | 10451 | 29550843 |
| Illusion | 18.22 | 16.16 | 8 | 13225 | 694 | 29560600 |
| Parkinsonism | 17.78 | 16.16 | 19 | 13214 | 7259 | 29554035 |
| Paranoia | 17.74 | 16.16 | 22 | 13211 | 9855 | 29551439 |
| Medication error | 17.64 | 16.16 | 33 | 13200 | 21178 | 29540116 |
| Application site erythema | 17.01 | 16.16 | 11 | 13222 | 2088 | 29559206 |
| Sedation | 16.93 | 16.16 | 29 | 13204 | 17376 | 29543918 |
| Oesophageal dilatation | 16.79 | 16.16 | 5 | 13228 | 140 | 29561154 |
| Abnormal dreams | 16.79 | 16.16 | 18 | 13215 | 6902 | 29554392 |
| Therapeutic response unexpected | 16.75 | 16.16 | 20 | 13213 | 8618 | 29552676 |
| Restlessness | 16.63 | 16.16 | 33 | 13200 | 22112 | 29539182 |
| Seizure | 16.63 | 16.16 | 84 | 13149 | 93039 | 29468255 |
| Accidental poisoning | 16.59 | 16.16 | 7 | 13226 | 551 | 29560743 |
| Neutropenia | 16.32 | 16.16 | 21 | 13212 | 131690 | 29429604 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Fall | 393.37 | 14.07 | 649 | 25736 | 416177 | 64056170 |
| Confusional state | 340.16 | 14.07 | 473 | 25912 | 260671 | 64211676 |
| Hallucination | 302.01 | 14.07 | 245 | 26140 | 72543 | 64399804 |
| Aggression | 218.27 | 14.07 | 168 | 26217 | 46064 | 64426283 |
| Agitation | 205.10 | 14.07 | 215 | 26170 | 88152 | 64384195 |
| Dementia | 185.55 | 14.07 | 112 | 26273 | 20654 | 64451693 |
| Somnolence | 177.69 | 14.07 | 307 | 26078 | 203338 | 64269009 |
| Abnormal behaviour | 160.46 | 14.07 | 123 | 26262 | 33499 | 64438848 |
| Product administration interrupted | 121.02 | 14.07 | 36 | 26349 | 1102 | 64471245 |
| Myoclonus | 117.88 | 14.07 | 91 | 26294 | 25027 | 64447320 |
| Delirium | 113.95 | 14.07 | 141 | 26244 | 69053 | 64403294 |
| Bradycardia | 111.92 | 14.07 | 185 | 26200 | 118034 | 64354313 |
| Death | 105.51 | 14.07 | 433 | 25952 | 482272 | 63990075 |
| Delusion | 101.85 | 14.07 | 73 | 26312 | 17941 | 64454406 |
| Body tinea | 95.74 | 14.07 | 31 | 26354 | 1262 | 64471085 |
| Psychomotor hyperactivity | 89.69 | 14.07 | 62 | 26323 | 14389 | 64457958 |
| Pleurothotonus | 85.33 | 14.07 | 33 | 26352 | 2269 | 64470078 |
| Gait disturbance | 83.73 | 14.07 | 204 | 26181 | 171951 | 64300396 |
| Loss of consciousness | 82.18 | 14.07 | 185 | 26200 | 148180 | 64324167 |
| Infection susceptibility increased | 76.55 | 14.07 | 32 | 26353 | 2694 | 64469653 |
| Orthostatic hypotension | 76.53 | 14.07 | 95 | 26290 | 46643 | 64425704 |
| Hallucination, visual | 75.96 | 14.07 | 74 | 26311 | 27760 | 64444587 |
| Arthralgia | 64.40 | 14.07 | 52 | 26333 | 442208 | 64030139 |
| Pneumonia aspiration | 63.23 | 14.07 | 98 | 26287 | 59173 | 64413174 |
| Inhibitory drug interaction | 61.70 | 14.07 | 30 | 26355 | 3597 | 64468750 |
| Seizure | 60.12 | 14.07 | 177 | 26208 | 166715 | 64305632 |
| Asthenia | 55.33 | 14.07 | 331 | 26054 | 427713 | 64044634 |
| Syncope | 53.76 | 14.07 | 164 | 26221 | 157471 | 64314876 |
| Eosinophilic pleural effusion | 53.75 | 14.07 | 14 | 26371 | 259 | 64472088 |
| Glucose tolerance impaired | 53.06 | 14.07 | 33 | 26352 | 6410 | 64465937 |
| Urinary tract infection | 52.95 | 14.07 | 211 | 26174 | 231385 | 64240962 |
| Drug hypersensitivity | 52.53 | 14.07 | 16 | 26369 | 237799 | 64234548 |
| Disorientation | 52.28 | 14.07 | 87 | 26298 | 55741 | 64416606 |
| Sialoadenitis | 52.08 | 14.07 | 21 | 26364 | 1612 | 64470735 |
| Rheumatoid arthritis | 52.00 | 14.07 | 4 | 26381 | 164290 | 64308057 |
| Speech disorder | 51.53 | 14.07 | 80 | 26305 | 48361 | 64423986 |
| Depressed level of consciousness | 51.27 | 14.07 | 107 | 26278 | 81329 | 64391018 |
| Inappropriate antidiuretic hormone secretion | 51.21 | 14.07 | 54 | 26331 | 22235 | 64450112 |
| Febrile neutropenia | 50.77 | 14.07 | 8 | 26377 | 187649 | 64284698 |
| Dysphagia | 49.16 | 14.07 | 124 | 26261 | 106688 | 64365659 |
| Mental status changes | 49.04 | 14.07 | 89 | 26296 | 61073 | 64411274 |
| Impaired quality of life | 47.94 | 14.07 | 31 | 26354 | 6440 | 64465907 |
| Cognitive disorder | 47.82 | 14.07 | 83 | 26302 | 55004 | 64417343 |
| Dyskinesia | 47.53 | 14.07 | 69 | 26316 | 39319 | 64433028 |
| Joint swelling | 46.65 | 14.07 | 15 | 26370 | 215367 | 64256980 |
| Gait inability | 46.51 | 14.07 | 71 | 26314 | 42297 | 64430050 |
| Pain | 45.01 | 14.07 | 100 | 26285 | 553411 | 63918936 |
| Sopor | 44.91 | 14.07 | 58 | 26327 | 29603 | 64442744 |
| Infusion related reaction | 42.31 | 14.07 | 8 | 26377 | 164459 | 64307888 |
| Tremor | 42.19 | 14.07 | 145 | 26240 | 148085 | 64324262 |
| Failure to thrive | 40.93 | 14.07 | 34 | 26351 | 10370 | 64461977 |
| Dementia with Lewy bodies | 40.61 | 14.07 | 14 | 26371 | 693 | 64471654 |
| Balance disorder | 40.26 | 14.07 | 99 | 26286 | 83827 | 64388520 |
| Electrocardiogram QT prolonged | 39.47 | 14.07 | 95 | 26290 | 79353 | 64392994 |
| Accidental overdose | 39.35 | 14.07 | 58 | 26327 | 33499 | 64438848 |
| Altered state of consciousness | 38.10 | 14.07 | 61 | 26324 | 37841 | 64434506 |
| Bone density decreased | 38.06 | 14.07 | 32 | 26353 | 9920 | 64462427 |
| Posture abnormal | 37.37 | 14.07 | 21 | 26364 | 3385 | 64468962 |
| Hypersomnia | 37.05 | 14.07 | 43 | 26342 | 19674 | 64452673 |
| Prescribed underdose | 36.76 | 14.07 | 41 | 26344 | 17974 | 64454373 |
| Subdural haematoma | 36.58 | 14.07 | 51 | 26334 | 28003 | 64444344 |
| Incoherent | 36.05 | 14.07 | 27 | 26358 | 7091 | 64465256 |
| Spur cell anaemia | 34.91 | 14.07 | 8 | 26377 | 84 | 64472263 |
| Electrocardiogram PR prolongation | 34.69 | 14.07 | 15 | 26370 | 1372 | 64470975 |
| Medication error | 34.22 | 14.07 | 68 | 26317 | 49898 | 64422449 |
| Sedation | 34.08 | 14.07 | 61 | 26324 | 41401 | 64430946 |
| Hip fracture | 33.46 | 14.07 | 48 | 26337 | 27051 | 64445296 |
| Decreased appetite | 32.79 | 14.07 | 212 | 26173 | 281077 | 64191270 |
| Hypernatraemia | 32.49 | 14.07 | 32 | 26353 | 12157 | 64460190 |
| Lack of spontaneous speech | 32.42 | 14.07 | 9 | 26376 | 214 | 64472133 |
| Encephalopathy | 32.13 | 14.07 | 73 | 26312 | 58746 | 64413601 |
| Disturbance in attention | 31.94 | 14.07 | 59 | 26326 | 41015 | 64431332 |
| Abdominal pain | 31.94 | 14.07 | 49 | 26336 | 312326 | 64160021 |
| Memory impairment | 31.89 | 14.07 | 92 | 26293 | 85590 | 64386757 |
| Poor quality sleep | 31.78 | 14.07 | 39 | 26346 | 18912 | 64453435 |
| Swelling | 31.56 | 14.07 | 13 | 26372 | 160205 | 64312142 |
| Hypophagia | 30.96 | 14.07 | 57 | 26328 | 39530 | 64432817 |
| Aphasia | 30.86 | 14.07 | 58 | 26327 | 40848 | 64431499 |
| Cerebral haemorrhage | 30.83 | 14.07 | 66 | 26319 | 51024 | 64421323 |
| Hyponatraemia | 30.59 | 14.07 | 131 | 26254 | 148208 | 64324139 |
| Purpura | 29.74 | 14.07 | 36 | 26349 | 17210 | 64455137 |
| Behaviour disorder | 29.71 | 14.07 | 20 | 26365 | 4442 | 64467905 |
| Lethargy | 29.02 | 14.07 | 80 | 26305 | 72514 | 64399833 |
| Arthropathy | 28.83 | 14.07 | 7 | 26378 | 120960 | 64351387 |
| Dehydration | 28.79 | 14.07 | 169 | 26216 | 216594 | 64255753 |
| Alopecia | 28.73 | 14.07 | 16 | 26369 | 165674 | 64306673 |
| Sinusitis | 28.49 | 14.07 | 12 | 26373 | 145916 | 64326431 |
| Neutropenia | 28.10 | 14.07 | 34 | 26351 | 239590 | 64232757 |
| Head injury | 27.86 | 14.07 | 49 | 26336 | 32793 | 64439554 |
| Dyspnoea | 27.44 | 14.07 | 177 | 26208 | 718497 | 63753850 |
| Neuroleptic malignant syndrome | 26.18 | 14.07 | 41 | 26344 | 24955 | 64447392 |
| Contraindicated product administered | 26.17 | 14.07 | 6 | 26379 | 107823 | 64364524 |
| Maternal exposure during pregnancy | 26.12 | 14.07 | 4 | 26381 | 95880 | 64376467 |
| Restlessness | 25.88 | 14.07 | 53 | 26332 | 39732 | 64432615 |
| Mixed dementia | 25.81 | 14.07 | 8 | 26377 | 282 | 64472065 |
| Foaming at mouth | 25.56 | 14.07 | 13 | 26372 | 1716 | 64470631 |
| Crying | 25.41 | 14.07 | 36 | 26349 | 20054 | 64452293 |
| Bradyarrhythmia | 25.40 | 14.07 | 17 | 26368 | 3741 | 64468606 |
| Nasopharyngitis | 24.98 | 14.07 | 26 | 26359 | 196047 | 64276300 |
| Cerebral atrophy | 24.97 | 14.07 | 22 | 26363 | 7263 | 64465084 |
| Mania | 24.89 | 14.07 | 32 | 26353 | 16254 | 64456093 |
| Stomatitis | 24.86 | 14.07 | 7 | 26378 | 109598 | 64362749 |
| Urinary retention | 24.61 | 14.07 | 59 | 26326 | 49142 | 64423205 |
| Sinus bradycardia | 24.60 | 14.07 | 38 | 26347 | 22855 | 64449492 |
| Urinary incontinence | 24.51 | 14.07 | 49 | 26336 | 36102 | 64436245 |
| Hyperlipidaemia | 24.50 | 14.07 | 38 | 26347 | 22938 | 64449409 |
| Dizziness | 23.93 | 14.07 | 275 | 26110 | 429888 | 64042459 |
| Product adhesion issue | 23.87 | 14.07 | 14 | 26371 | 2445 | 64469902 |
| Incontinence | 23.80 | 14.07 | 27 | 26358 | 12054 | 64460293 |
| Generalised tonic-clonic seizure | 23.49 | 14.07 | 51 | 26334 | 39806 | 64432541 |
| Akinesia | 23.42 | 14.07 | 15 | 26370 | 3064 | 64469283 |
| Impaired work ability | 23.41 | 14.07 | 30 | 26355 | 15189 | 64457158 |
| Parkinsonism | 23.17 | 14.07 | 29 | 26356 | 14344 | 64458003 |
| Rash | 22.97 | 14.07 | 103 | 26282 | 458446 | 64013901 |
| Condition aggravated | 22.96 | 14.07 | 243 | 26142 | 372183 | 64100164 |
| Hyporesponsive to stimuli | 22.25 | 14.07 | 12 | 26373 | 1785 | 64470562 |
| Emotional poverty | 22.21 | 14.07 | 9 | 26376 | 700 | 64471647 |
| International normalised ratio increased | 22.11 | 14.07 | 77 | 26308 | 79090 | 64393257 |
| Exposure during pregnancy | 21.71 | 14.07 | 3 | 26382 | 77672 | 64394675 |
| Amyloid related imaging abnormality-oedema/effusion | 21.37 | 14.07 | 5 | 26380 | 58 | 64472289 |
| Anger | 21.09 | 14.07 | 29 | 26356 | 15712 | 64456635 |
| Chorea | 21.05 | 14.07 | 12 | 26373 | 1988 | 64470359 |
| Skin disorder | 20.57 | 14.07 | 39 | 26346 | 27641 | 64444706 |
| Pain in extremity | 20.51 | 14.07 | 60 | 26325 | 303025 | 64169322 |
| Immobile | 20.29 | 14.07 | 18 | 26367 | 5997 | 64466350 |
| Paranoia | 20.24 | 14.07 | 29 | 26356 | 16323 | 64456024 |
| Epilepsy | 19.86 | 14.07 | 43 | 26342 | 33488 | 64438859 |
| Akathisia | 19.80 | 14.07 | 24 | 26361 | 11486 | 64460861 |
| Systemic lupus erythematosus | 19.48 | 14.07 | 4 | 26381 | 77608 | 64394739 |
| Headache | 19.36 | 14.07 | 132 | 26253 | 529335 | 63943012 |
| Hypersensitivity | 18.94 | 14.07 | 32 | 26353 | 196420 | 64275927 |
| Pruritus | 18.93 | 14.07 | 65 | 26320 | 312335 | 64160012 |
| Tardive dyskinesia | 18.91 | 14.07 | 21 | 26364 | 9157 | 64463190 |
| Aptyalism | 18.72 | 14.07 | 8 | 26377 | 711 | 64471636 |
| Drug intolerance | 18.71 | 14.07 | 30 | 26355 | 187962 | 64284385 |
| Nausea | 18.61 | 14.07 | 219 | 26166 | 785581 | 63686766 |
| Drug interaction | 18.58 | 14.07 | 228 | 26157 | 361855 | 64110492 |
| Irritability | 18.30 | 14.07 | 44 | 26341 | 36702 | 64435645 |
| Eating disorder | 18.21 | 14.07 | 28 | 26357 | 16777 | 64455570 |
| Dysstasia | 17.61 | 14.07 | 33 | 26352 | 23182 | 64449165 |
| Haemorrhagic stroke | 17.53 | 14.07 | 21 | 26364 | 9930 | 64462417 |
| Oral herpes | 17.45 | 14.07 | 32 | 26353 | 22120 | 64450227 |
| Hyperglycaemic hyperosmolar nonketotic syndrome | 17.25 | 14.07 | 10 | 26375 | 1709 | 64470638 |
| Completed suicide | 17.01 | 14.07 | 42 | 26343 | 224372 | 64247975 |
| Conduction disorder | 16.71 | 14.07 | 12 | 26373 | 2956 | 64469391 |
| Lower respiratory tract infection | 16.59 | 14.07 | 9 | 26376 | 94605 | 64377742 |
| Abdominal pain upper | 16.43 | 14.07 | 29 | 26356 | 175001 | 64297346 |
| Pyrexia | 16.35 | 14.07 | 148 | 26237 | 558496 | 63913851 |
| Suicidal ideation | 16.28 | 14.07 | 62 | 26323 | 66480 | 64405867 |
| Cough | 16.26 | 14.07 | 66 | 26319 | 302082 | 64170265 |
| Metastases to central nervous system | 16.24 | 14.07 | 24 | 26361 | 13888 | 64458459 |
| Cerebral infarction | 16.17 | 14.07 | 45 | 26340 | 40999 | 64431348 |
| Electrocardiogram J wave | 16.14 | 14.07 | 4 | 26381 | 60 | 64472287 |
| Unresponsive to stimuli | 15.83 | 14.07 | 51 | 26334 | 50342 | 64422005 |
| Freezing phenomenon | 15.53 | 14.07 | 9 | 26376 | 1537 | 64470810 |
| Illusion | 15.40 | 14.07 | 9 | 26376 | 1561 | 64470786 |
| Drowning | 15.21 | 14.07 | 7 | 26378 | 742 | 64471605 |
| Injection site erythema | 15.19 | 14.07 | 5 | 26380 | 70795 | 64401552 |
| Granulocytopenia | 15.15 | 14.07 | 20 | 26365 | 10420 | 64461927 |
| Nasal congestion | 15.13 | 14.07 | 3 | 26382 | 59655 | 64412692 |
| Ataxia | 15.05 | 14.07 | 30 | 26355 | 22054 | 64450293 |
| Neuropsychological test abnormal | 15.04 | 14.07 | 3 | 26382 | 15 | 64472332 |
| Drug-device interaction | 14.97 | 14.07 | 4 | 26381 | 82 | 64472265 |
| Oropharyngeal pain | 14.80 | 14.07 | 9 | 26376 | 88858 | 64383489 |
| Therapeutic drug monitoring analysis not performed | 14.75 | 14.07 | 8 | 26377 | 1204 | 64471143 |
| Device pacing issue | 14.70 | 14.07 | 4 | 26381 | 88 | 64472259 |
| Arthritis | 14.66 | 14.07 | 8 | 26377 | 83806 | 64388541 |
| Diet refusal | 14.50 | 14.07 | 7 | 26378 | 826 | 64471521 |
| Infection | 14.48 | 14.07 | 34 | 26351 | 184846 | 64287501 |
| Executive dysfunction | 14.44 | 14.07 | 5 | 26380 | 251 | 64472096 |
| Serotonin syndrome | 14.43 | 14.07 | 42 | 26343 | 39240 | 64433107 |
| Cerebrovascular accident | 14.38 | 14.07 | 101 | 26284 | 137482 | 64334865 |
| Marasmus | 14.23 | 14.07 | 7 | 26378 | 861 | 64471486 |
| Wrong patient received product | 14.19 | 14.07 | 12 | 26373 | 3750 | 64468597 |
| Decubitus ulcer | 14.09 | 14.07 | 22 | 26363 | 13357 | 64458990 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06DA52 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases |
| ATC | N06DA53 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases |
| ATC | N06DX01 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Other anti-dementia drugs |
| FDA MoA | N0000020015 | NMDA Receptor Antagonists |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018691 | Excitatory Amino Acid Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| FDA EPC | N0000175745 | N-methyl-D-aspartate Receptor Antagonist |
| CHEBI has role | CHEBI:35469 | antidepressants |
| CHEBI has role | CHEBI:48407 | antiparkinson agent |
| CHEBI has role | CHEBI:48560 | dopaminergic agents |
| CHEBI has role | CHEBI:60643 | N-methyl-D-aspartate receptor antagonists |
| CHEBI has role | CHEBI:63726 | neuroprotective agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Moderate to Severe Alzheimer's Type Dementia | indication | ||
| Acute nephropathy | contraindication | 58574008 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.37 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 10MG;14MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8173708 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;14MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8283379 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;14MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8338486 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;14MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8362085 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;14MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580858 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;21MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8173708 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;21MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8283379 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;21MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8338486 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;21MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8362085 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;21MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580858 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;28MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8173708 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;28MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8283379 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;28MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8338486 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;28MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8362085 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;28MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580858 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;7MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8173708 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;7MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8283379 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;7MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8338486 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;7MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8362085 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;7MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8580858 | Nov. 22, 2025 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 14MG | NAMENDA XR | ALLERGAN | N022525 | June 21, 2010 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 21MG | NAMENDA XR | ALLERGAN | N022525 | June 21, 2010 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 28MG | NAMENDA XR | ALLERGAN | N022525 | June 21, 2010 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 7MG | NAMENDA XR | ALLERGAN | N022525 | June 21, 2010 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;14MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;21MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;28MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;7MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8039009 | March 24, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;14MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8058291 | Dec. 5, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;21MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8058291 | Dec. 5, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;28MG | NAMZARIC | ALLERGAN | N206439 | Dec. 23, 2014 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8058291 | Dec. 5, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
| 10MG;7MG | NAMZARIC | ALLERGAN | N206439 | July 18, 2016 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8058291 | Dec. 5, 2029 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Ion channel | NEGATIVE ALLOSTERIC MODULATOR | IC50 | 5.02 | CHEMBL | CHEMBL | |||
| Glutamate NMDA receptor; GRIN1/GRIN2B | Ion channel | NEGATIVE ALLOSTERIC MODULATOR | IC50 | 5.26 | CHEMBL | CHEMBL | |||
| Glutamate NMDA receptor; GRIN1/GRIN2A | Ion channel | NEGATIVE ALLOSTERIC MODULATOR | IC50 | 9.02 | CHEMBL | CHEMBL | |||
| Glutamate receptor ionotropic, NMDA 3A | Ion channel | NEGATIVE ALLOSTERIC MODULATOR | WOMBAT-PK | CHEMBL | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 4.57 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 3A | Ion channel | WOMBAT-PK | |||||||
| Glutamate receptor ionotropic, NMDA 2C | Ion channel | Ki | 6.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021409 | VUID |
| N0000148824 | NUI |
| D04905 | KEGG_DRUG |
| 41100-52-1 | SECONDARY_CAS_RN |
| 4021409 | VANDF |
| C0025242 | UMLSCUI |
| CHEBI:64312 | CHEBI |
| 377 | PDB_CHEM_ID |
| CHEMBL1699 | ChEMBL_ID |
| CHEMBL807 | ChEMBL_ID |
| DB01043 | DRUGBANK_ID |
| D008559 | MESH_DESCRIPTOR_UI |
| 4054 | PUBCHEM_CID |
| 3952 | INN_ID |
| 4253 | IUPHAR_LIGAND_ID |
| W8O17SJF3T | UNII |
| 236685 | RXNORM |
| 169783 | MMSL |
| 17635 | MMSL |
| 203022 | MMSL |
| 47628 | MMSL |
| d04899 | MMSL |
| 006597 | NDDF |
| 006598 | NDDF |
| 406457005 | SNOMEDCT_US |
| 406458000 | SNOMEDCT_US |
| 426610008 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0850 | SOLUTION | 10 mg | ORAL | ANDA | 32 sections |
| Namzaric | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0456-1207 | CAPSULE | 7 mg | ORAL | NDA | 31 sections |
| Namzaric | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0456-1214 | CAPSULE | 14 mg | ORAL | NDA | 31 sections |
| Namzaric | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0456-1221 | CAPSULE | 21 mg | ORAL | NDA | 31 sections |
| Namzaric | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0456-1228 | CAPSULE | 28 mg | ORAL | NDA | 31 sections |
| Namenda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-3205 | TABLET | 5 mg | ORAL | NDA | 28 sections |
| Namenda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-3210 | TABLET | 10 mg | ORAL | NDA | 28 sections |
| NamendaXR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-3407 | CAPSULE, EXTENDED RELEASE | 7 mg | ORAL | NDA | 28 sections |
| NamendaXR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-3414 | CAPSULE, EXTENDED RELEASE | 14 mg | ORAL | NDA | 28 sections |
| NamendaXR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-3421 | CAPSULE, EXTENDED RELEASE | 21 mg | ORAL | NDA | 28 sections |
| NamendaXR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-3428 | CAPSULE, EXTENDED RELEASE | 28 mg | ORAL | NDA | 28 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1221 | TABLET | 5 mg | ORAL | ANDA | 27 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1221 | TABLET | 5 mg | ORAL | ANDA | 27 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1222 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1222 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1943 | SOLUTION | 2 mg | ORAL | ANDA | 28 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1943 | SOLUTION | 2 mg | ORAL | ANDA | 28 sections |
| memantine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3870 | TABLET | 5 mg | ORAL | NDA | 26 sections |
| memantine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3875 | TABLET | 10 mg | ORAL | NDA | 26 sections |
| Memantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8100 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
| Memantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8192 | TABLET | 5 mg | ORAL | ANDA | 27 sections |
| memantine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8264 | CAPSULE, EXTENDED RELEASE | 28 mg | ORAL | ANDA | 24 sections |
| Memantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8319 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1112 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 30 sections |
| Memantine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1113 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 30 sections |
| Memantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6505 | TABLET | 5 mg | ORAL | ANDA | 26 sections |
| Memantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6506 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
| memantine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6734 | CAPSULE, EXTENDED RELEASE | 7 mg | ORAL | ANDA | 24 sections |
| memantine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6735 | CAPSULE, EXTENDED RELEASE | 28 mg | ORAL | ANDA | 24 sections |
| memantine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6736 | CAPSULE, EXTENDED RELEASE | 14 mg | ORAL | ANDA | 24 sections |